Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22210637 | 0.83 | PDE4A (0.30) | — | |
| SCHEMBL22477682 | 0.83 | PDE4A (0.30) | — | |
| SCHEMBL21363440 | 0.81 | ALDH1A1 (0.37) | ALDH1A1LMNA | |
| SCHEMBL21363381 | 0.81 | TRPA1 (0.34) | ALDH1A1LMNA | |
| SCHEMBL21363377 | 0.79 | TRPA1 (0.36) | LMNA | |
| SCHEMBL21363374 | 0.78 | TRPA1 (0.37) | ALDH1A1LMNA | |
| SCHEMBL21363490 | 0.76 | ALDH1A1 (0.32) | ALDH1A1LMNA | |
| SCHEMBL21363508 | 0.76 | TRPA1 (0.39) | ALDH1A1LMNA | |
| SCHEMBL21363439 | 0.75 | ADORA2A (0.41) | ALDH1A1LMNA | |
| SCHEMBL21363596 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | ALDH1A1 721/4885LMNA 3183/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | ALDH1A1 721/4885LMNA 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.